Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
26.40    -0.20 (-0.75%)
Bid:
26.10
Ask:
27.40
Spread: 1.30 (4.981%)
Market Cap: £113.65m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Dividend Timetable

20 Sep 2022 07:01

RNS Number : 9264Z
EKF Diagnostics Holdings PLC
20 September 2022
 

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

Dividend Timetable

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, confirms that, further to the passing of the resolution at the AGM, a cash dividend of 1.2p per ordinary share will be paid in relation to its 2021 results as per the below timetable. The dividend will be paid to shareholders, on the register at close of business on 4 November 2022, on 1 December 2022.

 

The dividend timetable dates are detailed below:

 

Ex-dividend date:

3 November 2022

Record date:

4 November 2022

Payment date:

1 December 2022

 

 

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Mike Salter, CEO / Marc Davies, CFO

 Tel: +44 (0)29 2071 0570

Singer Capital Markets (Nominated Adviser & Joint Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / George Tzimas / Oliver Platts

Investec Bank plc (Joint Broker)

Tel: +44 (0)20 7597 4000

Gary Clarence / Daniel Adams / Ben Farrow

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

 

Point-of-Care

Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.

 

Central Laboratory

Clinical chemistry, Small lab analysers, Centrifuges

Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycated Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin

 

Life Sciences

Enzyme fermentation, Custom products and Bulk fermentation

 

Contract Manufacturing

Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits

 

Laboratory Testing

Laboratory testing services certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPUCPBUPPGQB
Date   Source Headline
24th Nov 202511:47 amRNSShare Buyback
19th Nov 20253:41 pmRNSShare Buyback
17th Nov 20252:12 pmRNSShare Buyback
4th Nov 20251:54 pmRNSTotal Voting Rights
3rd Nov 202510:19 amRNSShare Buyback
31st Oct 20251:02 pmRNSShare Buyback
30th Oct 202512:55 pmRNSShare Buyback
29th Oct 202510:59 amRNSShare Buyback
28th Oct 202511:00 amRNSShare Buyback
27th Oct 202510:25 amRNSShare Buyback
24th Oct 202511:10 amRNSShare Buyback
23rd Oct 202510:10 amRNSShare Buyback
21st Oct 20253:10 pmRNSShare Buyback & Extension of Buyback Programme
20th Oct 202512:24 pmRNSShare Buyback (Replacement)
20th Oct 202511:36 amRNSShare Buyback
17th Oct 20257:00 amRNSShare Buyback
15th Oct 202512:30 pmRNSShare Buyback
19th Sep 20254:25 pmRNSHolding(s) in Company
16th Sep 20257:15 amRNSLong Term Incentive Plan
16th Sep 20257:00 amRNSHalf-year Report
10th Sep 20257:00 amRNSNotice of interim results
26th Aug 20257:00 amRNSHematology contracts signed worth EUR 4.65m
28th Jul 20257:00 amRNSH1 2025 Trading Update
25th Jun 202512:00 pmRNSCancellation of Treasury Shares & TVR
17th Jun 20255:24 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSTotal Voting Rights
21st May 20257:00 amRNSAdditional Share Buyback Programme
20th May 20252:41 pmRNSResult of AGM and Voting Results
20th May 20257:00 amRNSAGM Statement
13th May 20257:00 amRNSShare Buyback & Completion of Share Buyback Prog.
9th May 20251:42 pmRNSShare Buyback
8th May 20259:11 amRNSShare Buyback
6th May 20253:55 pmRNSShare Buyback
29th Apr 20257:00 amRNSShare Buyback
28th Apr 20257:00 amRNSPosting of AR&A & Notice of AGM
9th Apr 20257:00 amRNSShare Buyback
8th Apr 20257:00 amRNSShare Buyback
7th Apr 20252:58 pmRNSShare Buyback
7th Apr 20257:00 amRNSShare Buyback
2nd Apr 20257:00 amRNSShare Buyback
1st Apr 20257:00 amRNSShare Buyback
26th Mar 20257:00 amRNSDirector/PDMR Shareholding
25th Mar 20257:00 amRNSAppointment of CEO
25th Mar 20257:00 amRNSFull year results
6th Mar 20257:00 amRNSNotice of Results & Investor Presentations
7th Feb 20253:04 pmRNSHolding(s) in Company
6th Feb 202511:34 amRNSHolding(s) in Company
29th Jan 20257:00 amRNSFY 2024 Trading Update
17th Sep 20247:00 amRNSHalf-year Report
3rd Sep 20247:00 amRNSNotice of Results and Investor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.